Goodrich Katherine 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) Director Katherine Goodrich Sells Shares
What Happened
Katherine Goodrich, a director of Tarsus Pharmaceuticals, sold 2,954 shares on June 15, 2026 at $62.08 per share, generating proceeds of $183,384. The transaction is reported as a sale (S) effected in the open market or private sale.
Key Details
- Transaction date and price: June 15, 2026 — 2,954 shares at $62.08 each.
- Total value: $183,384 (gross proceeds).
- Ownership after transaction: Not specified in the information provided on the filing.
- Filing/receipt: Form 4 filed June 17, 2026 for the June 15 transaction (filed within the typical two-business-day window).
- Footnote: The sale was executed automatically under a Rule 10b5-1 trading plan adopted by Goodrich on February 27, 2026 (footnote F1).
Context
A 10b5-1 plan allows insiders to sell shares according to a pre-set schedule and is often used for routine, pre-arranged disposals rather than reflecting a change in view about the company. Sales are generally less informative than purchases about insider confidence; this filing documents a planned sale, not an ad hoc trade.
Insider Transaction Report
Form 4
Goodrich Katherine
Director
Transactions
- Sale
Common Stock
[F1]2026-06-15$62.08/sh−2,954$183,384→ 2,233 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact|2026-06-17